CoChat
Cited by 1,200

The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Open access
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L.D., Newbold, K., Papotti, M.G., Berruti, A. · 2019 · Annals of Oncology

Abstract

This ESMO Clinical Practice Guidelines provide updated state-of-the-art recommendations on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a multidisciplinary author panel and accompanied by level of evidence and grade of recommendation, depending on the strength of supporting data and magnitude of benefit from particular interventions

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz400

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 34

  1. 2019, European Network of Cancer Registries Factsheets
  2. Maletta, 2016, Cytological features of “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology, Hum Pathol, 54, 134, 10.1016/j.humpath.2016.03.014 · doi:10.1016/j.humpath.2016.03.014
  3. Williams, 2000, Guest editorial: two proposals regarding the terminology of thyroid tumors, Int J Surg Pathol, 8, 181, 10.1177/106689690000800304 · doi:10.1177/106689690000800304
  4. Randolph, 2011, The surgical management of goiter: Part II. Surgical treatment and results, Laryngoscope, 121, 68, 10.1002/lary.21091 · doi:10.1002/lary.21091
  5. Lamartina, 2018, Recent advances in managing differentiated thyroid cancer, F1000Res, 7, 86., 10.12688/f1000research.12811.1 · DOI
  6. Lamartina, 2016, ENDOCRINE TUMOURS: imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach, Eur J Endocrinol, 175, R185, 10.1530/EJE-16-0088 · doi:10.1530/eje-16-0088
  7. Robbins, 2008, The value of positron emission tomography (PET) in the management of patients with thyroid cancer, Best Pract Res Clin Endocrinol Metab, 22, 1047, 10.1016/j.beem.2008.10.001 · doi:10.1016/j.beem.2008.10.001
  8. Terroir, 2017, The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 44, 638, 10.1007/s00259-016-3551-x · doi:10.1007/s00259-016-3551-x
  9. Choksi, 2017, Skeletal complications and mortality in thyroid cancer: a population-based study, J Clin Endocrinol Metab, 102, 1254, 10.1210/jc.2016-3906 · doi:10.1210/jc.2016-3906
  10. Drost, 2017, Efficacy of postoperative radiation treatment for bone metastases in the extremities, Radiother Oncol, 124, 45, 10.1016/j.radonc.2017.05.010 · doi:10.1016/j.radonc.2017.05.010
  11. Deschamps, 2014, Percutaneous ablation of bone tumors, Diagn Interv Imaging, 95, 659, 10.1016/j.diii.2014.04.004 · doi:10.1016/j.diii.2014.04.004
  12. Deschamps, 2016, Percutaneous osteosynthesis in the pelvis in cancer patients, Eur Radiol, 26, 1631, 10.1007/s00330-015-3971-1 · doi:10.1007/s00330-015-3971-1
  13. de Baere, 2015, Interventional oncology for liver and lung metastases from colorectal cancer: the current state of the art, Diagn Interv Imaging, 96, 647, 10.1016/j.diii.2015.04.004 · DOI
  14. Venkatanarasimha, 2017, Radioembolisation of hepatocellular carcinoma: a primer, Clin Radiol, 72, 1002, 10.1016/j.crad.2017.07.021 · doi:10.1016/j.crad.2017.07.021
  15. Balmelli, 2018, Lenvatinib in advanced radioiodine-refractory thyroid cancer—a retrospective analysis of the Swiss Lenvatinib Named Patient Program, J Cancer, 9, 250, 10.7150/jca.22318 · doi:10.7150/jca.22318
  16. Brose, 2018, A phase 2 trial of cabozantinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma in the first-line setting, Int J Radiat Oncol Biol Phys, 100, 1311, 10.1016/j.ijrobp.2017.12.028 · doi:10.1016/j.ijrobp.2017.12.028
  17. Schlumberger, 2018, A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209, J Clin Oncol, 36, 6021., 10.1200/JCO.2018.36.15_suppl.6021 · doi:10.1200/jco.2018.36.15_suppl.6021
  18. Bogsrud, 2008, 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma, Thyroid, 18, 713, 10.1089/thy.2007.0350 · doi:10.1089/thy.2007.0350
  19. Sugitani, 2018, Management of anaplastic thyroid carcinoma: the fruits from the ATC research consortium of Japan, J Nippon Med Sch, 85, 18, 10.1272/jnms.2018_85-3 · doi:10.1272/jnms.2018_85-3
  20. Baek, 2017, Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012, Head Neck, 39, 133, 10.1002/hed.24559 · doi:10.1002/hed.24559
  21. Ito, 2012, Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors, Head Neck, 34, 230, 10.1002/hed.21721 · doi:10.1002/hed.21721
  22. Bhatia, 2010, Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy, Head Neck, 32, 829, 10.1002/hed.21257 · doi:10.1002/hed.21257
  23. Mohebati, 2014, Anaplastic thyroid carcinoma: a 25-year single-institution experience, Ann Surg Oncol, 21, 1665, 10.1245/s10434-014-3545-5 · doi:10.1245/s10434-014-3545-5
  24. Pezzi, 2017, Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base, Cancer, 123, 1653, 10.1002/cncr.30493 · doi:10.1002/cncr.30493
  25. Wang, 2006, Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens, Cancer, 107, 1786, 10.1002/cncr.22203 · doi:10.1002/cncr.22203
  26. Dandekar, 2009, Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis, Int J Radiat Oncol Biol Phys, 74, 518, 10.1016/j.ijrobp.2008.08.016 · doi:10.1016/j.ijrobp.2008.08.016
  27. Foote, 2011, Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy, Thyroid, 21, 25, 10.1089/thy.2010.0220 · doi:10.1089/thy.2010.0220
  28. Wirth, 2018, Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer, J Clin Oncol, 36, 6024, 10.1200/JCO.2018.36.15_suppl.6024 · doi:10.1200/jco.2018.36.15_suppl.6024
  29. Moley, 1999, Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection, Ann Surg, 229, 880, 10.1097/00000658-199906000-00016 · doi:10.1097/00000658-199906000-00016
  30. Treglia, 2012, PET imaging in recurrent medullary thyroid carcinoma, Int J Mol Imaging, 2012, 1
  31. Romero-Lluch, 2017, Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff, Eur J Nucl Med Mol Imaging, 44, 2004, 10.1007/s00259-017-3759-4 · doi:10.1007/s00259-017-3759-4
  32. Bodei, 2004, Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas, Cancer Biother Radiopharm, 19, 65, 10.1089/108497804773391694 · doi:10.1089/108497804773391694
  33. Fox, 2013, Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma, Clin Cancer Res, 19, 4239, 10.1158/1078-0432.CCR-13-0071 · doi:10.1158/1078-0432.ccr-13-0071
  34. Trimboli, 2018, Efficacy of vandetanib in treating locally advanced or metastatic medullary thyroid carcinoma according to RECIST criteria: a systematic review and meta-analysis, Front Endocrinol (Lausanne), 9, 224., 10.3389/fendo.2018.00224 · doi:10.3389/fendo.2018.00224

Cited by

See all 1,200

Metadata

Authors
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-12
Volume
30
Issue
12
Pages
1856-1883
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2975387808
Cited by
1,200
References
131
FWCI
67.80
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
ESMO

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.